Hanmi Science has patented a conjugate combining oxyntomodulin, an immunoglobulin Fc region, and a non-peptidyl polymer for treating obesity. The conjugate reduces food intake, suppresses gastric emptying, and facilitates lipolysis with improved efficacy and safety compared to native oxyntomodulin. GlobalData’s report on Hanmi Science gives a 360-degree view of the company including its patenting strategy. Buy the report here.

Smarter leaders trust GlobalData


Data Insights Hanmi Science Co Ltd - Company Profile

Buy the Report

Data Insights

The gold standard of business intelligence.

Find out more

According to GlobalData’s company profile on Hanmi Science, Hormone-based therapies for metabolic disorders was a key innovation area identified from patents. Hanmi Science's grant share as of January 2024 was 36%. Grant share is based on the ratio of number of grants to total number of patents.

Conjugate for obesity treatment with oxyntomodulin and immunoglobulin

Source: United States Patent and Trademark Office (USPTO). Credit: Hanmi Science Co Ltd

A recently granted patent (Publication Number: US11872283B2) discloses a novel conjugate designed for the treatment of obesity. The conjugate comprises an oxyntomodulin derivative with specific amino acid sequences, an immunoglobulin Fc region, and a non-peptidyl polymer that links the two components via covalent bonds. The oxyntomodulin derivative in the conjugate is capable of activating glucagon-like peptide-1 receptor, glucagon receptor, or both, thereby exhibiting anti-obesity effects. The non-peptidyl polymer used in the conjugate includes options such as polyethylene glycol, polysaccharides like dextran, and other polymers like hyaluronic acid.

Furthermore, the patent claims cover various aspects of the conjugate, including the specific amino acid sequences of the oxyntomodulin derivative, the types of non-peptidyl polymers that can be used, and the methods of preparing the conjugate. The patent also extends to pharmaceutical compositions containing the conjugate along with a pharmaceutically acceptable carrier. Additionally, methods for treating obesity using the conjugate, either alone or in combination with other specified agents like receptor agonists and enzyme inhibitors, are also included in the patent claims. This innovative approach to combating obesity through a unique conjugate opens up new possibilities for therapeutic interventions in this prevalent health condition.

To know more about GlobalData’s detailed insights on Hanmi Science, buy the report here.

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies